Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults

Healthy Clinical Trial

Official title:

Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults (Phosphate and Fibroblast Growth Factor 23 [FGF23]: Dietary and Molecular Mediators of Health and Disparities in Cardiovascular and Kidney Diseases)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02620449
• Other study ID #: F150728005
• Status: Completed
• Phase: N/A
• Start date: August 28, 2015
• Est. completion date: March 30, 2020

Study information

• Verified date: March 2021
• Source: University of Alabama at Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to learn more about how common food additives can affect phosphorus metabolism in people with normal kidney function and people with chronic kidney disease.

Description:

Disturbances in phosphate homeostasis are strongly associated with cardiovascular morbidity and mortality. High dietary phosphate intake plays a central role in the development of disturbed phosphate metabolism and is common in persons consuming typical American diets rich in processed and fast foods. An important reason for the high phosphate content of these foods is the widespread use of phosphate-based food additives in the food supply. Phosphate additives are heavily utilized by the food manufacturing industry to enhance the appearance, taste and shelf-life of processed foods, accounting for as much as 50% of total phosphate intake per day. Prior work from our group suggest that high phosphate additive intake has serious cardiovascular consequences. We showed that phosphate excess induces heart disease and inflammation in experimental studies, and associates with heart disease and death independently of classic risk factors in epidemiology studies. Further, we showed that high phosphate additive intake stimulates the secretion of fibroblast growth factor 23 (FGF23), a phosphate-regulatory hormone directly implicated in the pathogenesis of cardiovascular disease. Together, these data strongly suggest that high phosphate additive intake promotes cardiovascular disease, with important potential implications for efforts to reduce disparities in cardiovascular disease. This is because individuals with low socioeconomic status have limited means to purchase healthy foods, resulting in excessive consumption of processed foods rich in phosphate additives. Moreover, low income neighborhoods have a disproportionately high prevalence of individuals with chronic kidney disease and black individuals, both groups that have impaired ability to excrete excess phosphate. Together, these data support our overriding hypothesis that high phosphate additive intake is a novel target for reducing socioeconomic and racial disparities in cardiovascular. We will test this hypothesis in detailed feeding studies of 80 individuals fed standardized meals with low phosphate additive content for 6 weeks. We will investigate the impact of reducing phosphate additive intake on changes in FGF23 levels, inflammatory markers and vascular function, and test for effect modification by race and chronic kidney disease (CKD). The results of these studies will help determine whether high phosphate additive intake is a modifiable risk factor for disparities in cardiovascular disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 30, 2020
• Est. primary completion date: March 5, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• (i.) Inclusion criteria for healthy volunteers: =18 years of age, normal kidney function (eGFR > 60 and normal urinalysis).

Exclusion Criteria:

• Exclusion criteria for healthy volunteers will include:

• current smoking

• extreme obesity (BMI = 35 kg/m2)

• pregnancy or breastfeeding

• conditions affecting phosphate metabolism (e.g., hyper- or hypothyroidism; irregular menses for menstruating women)

• current intake of medications that impact phosphate metabolism (high-dose vitamin D, chronic antacid use)

• current use of blood pressure medications

• abnormal serum phosphate (= 4.6 or < 2.5 mg/dl) or calcium levels (= 10.6 or < 8.5 mg/dl)

• severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men).

• Inability to receive weekly shipments of food at home.

• Requirement for any special diet other than a regular diet.

• Allergies to any foods in the standardized diets (ii.) Inclusion criteria for CKD patients: =18 years of age, eGFR 20-50 ml/min

Exclusion criteria for CKD patients will include:

• clinical need for a low potassium, low sodium or low protein diet

• new or recent change (<3 months) in dosage of medications known to impact vascular reactivity

• current smoking

• poorly controlled hypertension (=160/100 mmHg)

• extreme obesity (BMI = 35 kg/m2)

• pregnancy or breastfeeding

• conditions affecting phosphate metabolism (e.g., hyper- or hypothyroidism)

• current intake of medications that impact phosphate metabolism (e.g., high-dose vitamin D)

• abnormal serum phosphate (= 4.6 or < 2.5 mg/dl) or calcium levels (= 10.6 or < 8.5 mg/dl)

• severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men).

• Inability to receive weekly shipments of food at home.

• Allergies to any foods in the standardized diets

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Healthy
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Other:
• Diet
Participants will be fed a low-additive diet as the primary intervention

Locations

Country	Name	City	State
United States	University of Alabama	Birmingham	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in circulating fibroblast growth factor 23 (FGF23) concentrations	Longitudinal change in FGF23 concentrations over 8 weeks	8 weeks
Primary	Change in brachial flow-mediated dilatation (FMD)	Longitudinal changes in FMD over 8 weeks	8 weeks
Primary	Change in pulse wave velocity (PWV)	longitudinal changes in PWV over 8 weeks	8 weeks